Olema says OP-3136 Phase 1 trial enrolls patients in breast cancer study

• Olema disclosed new preclinical findings on breast cancer drug palazestrant, which will be presented at AACR Annual Meeting on April 20, 2026.
• Data support palazestrant mechanism as a complete estrogen receptor antagonist, pointing to deeper pathway suppression than standard endocrine approaches.
• Separate preclinical results indicate OP-3136 combined with palazestrant produced synergistic anti-tumor activity in ER+/HER2- breast cancer models, reinforcing a combination strategy to address acquired resistance.
• Palazestrant remains in two Phase 3 trials, with top-line OPERA-01 monotherapy results anticipated in fall 2026.
• OP-3136 continues enrollment in an ongoing Phase 1 study, positioning it as Olema next clinical-stage asset alongside palazestrant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171601PRIMZONEFULLFEED9692069) on April 17, 2026, and is solely responsible for the information contained therein.